Coprinus comatus and Ganoderma lucidum interfere with androgen receptor function in LNCaP prostate cancer cells

Ben Zion Zaidman; Solomon P. Wasser; Eviatar Nevo; Jamal Mahajna

doi:10.1007/s11033-007-9059-5

Coprinus comatus and Ganoderma lucidum interfere with androgen receptor function in LNCaP prostate cancer cells

Ben Zion Zaidman, Solomon P. Wasser, Eviatar Nevo, Jamal Mahajna

Department of Evolutionary and Environmental Biology

Research output: Contribution to journal › Article › peer-review

Abstract

In this study, we screened a total of 201 diethyl ether, ethanol, and ethyl acetate fungal Basidiomycetes extracts for anti-androgenic activity. Based on our screened results in combination with the selective inhibition of prostate cancer LNCaP cells, we selected Coprinus comatus and Ganoderma lucidum for further evaluation. We demonstrated that ethanol and ethyl acetate extracts from C. comatus and G. lucidum, respectively, selectively inhibit dihydrotestosterone-induced LNCaP cell viability, suppress levels of secreted prostate-specific antigen in a dose-dependent manner, and cause a G1 phase arrest in LNCaP, but not in DU 145 and PC-3 cells. For the first time, to the best of our knowledge, we demonstrated that C. comatus and G. lucidum decreased androgen and glucocorticoide receptors transcriptional activity in breast cancer MDA-kb2 cells in a dose-dependent manner, and suppressed androgen receptor (AR) protein level in LNCaP and MDA-kb2 cells. Our findings suggest that AR and non-AR mediated mechanisms underlie the effects of C. comatus and G. lucidum.

Original language	English
Pages (from-to)	107-117
Number of pages	11
Journal	Molecular Biology Reports
Volume	35
Issue number	2
DOIs	https://doi.org/10.1007/s11033-007-9059-5
State	Published - Jun 2008

Bibliographical note

Funding Information:
Acknowledgments We thank R. Permut (Israel) for the English editing. This research was supported by the Ministry of Science and Technology of Israel, grant no. 3-0561.

Keywords

Androgen receptor
Coprinus comatus
Ganoderma lucidum
LNCaP
Prostate cancer

ASJC Scopus subject areas

Molecular Biology
Genetics

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s11033-007-9059-5

Cite this

@article{c79d12c5017143b08ae5abe30348b3d8,

title = "Coprinus comatus and Ganoderma lucidum interfere with androgen receptor function in LNCaP prostate cancer cells",

abstract = "In this study, we screened a total of 201 diethyl ether, ethanol, and ethyl acetate fungal Basidiomycetes extracts for anti-androgenic activity. Based on our screened results in combination with the selective inhibition of prostate cancer LNCaP cells, we selected Coprinus comatus and Ganoderma lucidum for further evaluation. We demonstrated that ethanol and ethyl acetate extracts from C. comatus and G. lucidum, respectively, selectively inhibit dihydrotestosterone-induced LNCaP cell viability, suppress levels of secreted prostate-specific antigen in a dose-dependent manner, and cause a G1 phase arrest in LNCaP, but not in DU 145 and PC-3 cells. For the first time, to the best of our knowledge, we demonstrated that C. comatus and G. lucidum decreased androgen and glucocorticoide receptors transcriptional activity in breast cancer MDA-kb2 cells in a dose-dependent manner, and suppressed androgen receptor (AR) protein level in LNCaP and MDA-kb2 cells. Our findings suggest that AR and non-AR mediated mechanisms underlie the effects of C. comatus and G. lucidum.",

keywords = "Androgen receptor, Coprinus comatus, Ganoderma lucidum, LNCaP, Prostate cancer",

author = "Zaidman, {Ben Zion} and Wasser, {Solomon P.} and Eviatar Nevo and Jamal Mahajna",

note = "Funding Information: Acknowledgments We thank R. Permut (Israel) for the English editing. This research was supported by the Ministry of Science and Technology of Israel, grant no. 3-0561.",

year = "2008",

month = jun,

doi = "10.1007/s11033-007-9059-5",

language = "English",

volume = "35",

pages = "107--117",

journal = "Molecular Biology Reports",

issn = "0301-4851",

publisher = "Springer Science and Business Media B.V.",

number = "2",

}

TY - JOUR

T1 - Coprinus comatus and Ganoderma lucidum interfere with androgen receptor function in LNCaP prostate cancer cells

AU - Zaidman, Ben Zion

AU - Wasser, Solomon P.

AU - Nevo, Eviatar

AU - Mahajna, Jamal

N1 - Funding Information: Acknowledgments We thank R. Permut (Israel) for the English editing. This research was supported by the Ministry of Science and Technology of Israel, grant no. 3-0561.

PY - 2008/6

Y1 - 2008/6

N2 - In this study, we screened a total of 201 diethyl ether, ethanol, and ethyl acetate fungal Basidiomycetes extracts for anti-androgenic activity. Based on our screened results in combination with the selective inhibition of prostate cancer LNCaP cells, we selected Coprinus comatus and Ganoderma lucidum for further evaluation. We demonstrated that ethanol and ethyl acetate extracts from C. comatus and G. lucidum, respectively, selectively inhibit dihydrotestosterone-induced LNCaP cell viability, suppress levels of secreted prostate-specific antigen in a dose-dependent manner, and cause a G1 phase arrest in LNCaP, but not in DU 145 and PC-3 cells. For the first time, to the best of our knowledge, we demonstrated that C. comatus and G. lucidum decreased androgen and glucocorticoide receptors transcriptional activity in breast cancer MDA-kb2 cells in a dose-dependent manner, and suppressed androgen receptor (AR) protein level in LNCaP and MDA-kb2 cells. Our findings suggest that AR and non-AR mediated mechanisms underlie the effects of C. comatus and G. lucidum.

AB - In this study, we screened a total of 201 diethyl ether, ethanol, and ethyl acetate fungal Basidiomycetes extracts for anti-androgenic activity. Based on our screened results in combination with the selective inhibition of prostate cancer LNCaP cells, we selected Coprinus comatus and Ganoderma lucidum for further evaluation. We demonstrated that ethanol and ethyl acetate extracts from C. comatus and G. lucidum, respectively, selectively inhibit dihydrotestosterone-induced LNCaP cell viability, suppress levels of secreted prostate-specific antigen in a dose-dependent manner, and cause a G1 phase arrest in LNCaP, but not in DU 145 and PC-3 cells. For the first time, to the best of our knowledge, we demonstrated that C. comatus and G. lucidum decreased androgen and glucocorticoide receptors transcriptional activity in breast cancer MDA-kb2 cells in a dose-dependent manner, and suppressed androgen receptor (AR) protein level in LNCaP and MDA-kb2 cells. Our findings suggest that AR and non-AR mediated mechanisms underlie the effects of C. comatus and G. lucidum.

KW - Androgen receptor

KW - Coprinus comatus

KW - Ganoderma lucidum

KW - LNCaP

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=44049107044&partnerID=8YFLogxK

U2 - 10.1007/s11033-007-9059-5

DO - 10.1007/s11033-007-9059-5

M3 - Article

C2 - 17431821

AN - SCOPUS:44049107044

SN - 0301-4851

VL - 35

SP - 107

EP - 117

JO - Molecular Biology Reports

JF - Molecular Biology Reports

IS - 2

ER -

Coprinus comatus and Ganoderma lucidum interfere with androgen receptor function in LNCaP prostate cancer cells

Abstract

Bibliographical note

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this